文献速递认知障碍与痴呆

基于淀粉样蛋白PET和tau-PET评估唐氏综合征患者出现症状性阿尔茨海默病的时间线:一项纵向队列研究

Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.
PubMed 文献 · Lancet Neurol · 2024-01-01

该前瞻性纵向观察队列研究纳入167名唐氏综合征成人(92名有纵向数据),利用淀粉样蛋白PET和tau-PET评估从淀粉样蛋白β阳性起至认知下降和痴呆的时间线。结果显示,mCRT总分差异在淀粉样蛋白β阳性后2.7年(95%CrI 0.2-5.4)开始出现,轻度认知障碍平均在淀粉样蛋白年龄7.4年(相当于56.8 centiloids)时观察到,痴呆平均在12.7年(相当于97.4 centiloids)时观察到。

要点

  • 唐氏综合征成人从淀粉样蛋白β阳性到认知下降和痴呆的时间线较短。
  • mCRT总分差异在淀粉样蛋白β阳性后2.7年开始检测到。
  • 轻度认知障碍平均在淀粉样蛋白年龄7.4年时出现,痴呆平均在12.7年时出现。

核心结论

  • 唐氏综合征患者从淀粉样蛋白β阳性及tau沉积开始至初始认知下降和痴呆的时间线较短。
  • 基于淀粉样蛋白年龄(或等效centiloid值)新建立的时间线对临床实践和阿尔茨海默病临床试验设计具有重要意义,且避免了基于实际年龄时间线的局限性。

研究设计与样本

  • 前瞻性、纵向、观察性队列研究,数据来自英国和美国的四个大学研究站点,属于阿尔茨海默生物标志物联盟-唐氏综合征(ABC-DS)研究。
  • 纳入标准为年龄25岁及以上、经标准化智商量表评估心理年龄至少3岁、核型分析确认21三体(完全型、嵌合型或易位型)的唐氏综合征患者。
  • 参与者在2017年至2022年间接受两次评估,两次访视间隔约32个月。
  • 评估包括淀粉样蛋白PET和tau-PET扫描,以及改良提示回忆测验(mCRT)和唐氏综合征精神状态检查(DSMSE)认知评估,研究伙伴完成国家任务组-痴呆早期检测筛查(NTG-EDSD)。
  • 共纳入167名唐氏综合征成人进行分析,其中92名有纵向数据。

主要发现

  • 广义线性回归显示,淀粉样蛋白年龄与认知表现之间呈显著二次关联,与tau之间呈三次关联,在基线和32个月随访时均如此。
  • 采用断棍回归模型,横断面模型中mCRT总分差异在淀粉样蛋白β阳性后2.7年(95%CrI 0.2至5.4;相当于29.8 centiloids)开始检测到。
  • 基于横断面数据,tau沉积增加在淀粉样蛋白β阳性后平均2.7-6.1年(相当于29.8-47.9 centiloids)开始。
  • 轻度认知障碍在平均淀粉样蛋白年龄7.4年(SD 6.6;相当于56.8 centiloids)时观察到,痴呆在平均淀粉样蛋白年龄12.7年(SD 5.6;相当于97.4 centiloids)时观察到。

临床怎么用

  • 作者认为,基于淀粉样蛋白年龄(或等效centiloid值)新建立的时间线对临床实践和阿尔茨海默病临床试验设计具有重要意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adults with Down syndrome are at risk for Alzheimer's disease. Natural history cohort studies have characterised the progression of Alzheimer's disease biomarkers in people with Down syndrome, with a focus on amyloid β-PET and tau-PET. In this study, we aimed to leverage these well characterised imaging biomarkers in a large cohort of individuals with Down syndrome, to examine the timeline to symptomatic Alzheimer's disease based on estimated years since the detection on PET of amyloid β-positivity, referred to here as amyloid age, and in relation to tau burden as assessed by PET. METHODS: In this prospective, longitudinal, observational cohort study, data were collected at four university research sites in the UK and USA as part of the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study. Eligible participants were aged 25 years or older with Down syndrome, had a mental age of at least 3 years (based on a standardised intelligence quotient test), and had trisomy 21 (full, mosaic, or translocation) confirmed through karyotyping. Participants were assessed twice between 2017 and 2022, with approximately 32 months between visits. Participants had amyloid-PET and tau-PET scans, and underwent cognitive assessment with the modified Cued Recall Test (mCRT) and the Down Syndrome Mental Status Examination (DSMSE) to assess cognitive functioning. Study partners completed the National Task Group-Early Detection Screen for Dementia (NTG-EDSD). Generalised linear models were used to assess the association between amyloid age (whereby 0 years equated to 18 centiloids) and mCRT, DSMSE, NTG-EDSD, and tau PET at baseline and the 32-month follow-up. Broken stick regression was used to identify the amyloid age that corresponded to decreases in cognitive performance and increases in tau PET after the onset of amyloid β positivity. FINDINGS: 167 adults with Down syndrome, of whom 92 had longitudinal data, were included in our analyses. Generalised linear regressions showed significant quadratic associations between amyloid age and cognitive performance and cubic associations between amyloid age and tau, both at baseline and at the 32-month follow-up. Using broken stick regression models, differences in mCRT total scores were detected beginning 2·7 years (95% credible interval [CrI] 0·2 to 5·4; equating to 29·8 centiloids) after the onset of amyloid β positivity in cross-sectional models. Based on cross-sectional data, increases in tau deposition started a mean of 2·7-6·1 years (equating to 29·8-47·9 centiloids) after the onset of amyloid β positivity. Mild cognitive impairment was observed at a mean amyloid age of 7·4 years (SD 6·6; equating to 56·8 centiloids) and dementia was observed at a mean amyloid age of 12·7 years (5·6; equating to 97·4 centiloids). INTERPRETATION: There is a short timeline to initial cognitive decline and dementia from onset of amyloid β positivity and tau deposition in people with Down syndrome. This newly established timeline based on amyloid age (or equivalent centiloid values) is important for clinical practice and informing the design of Alzheimer's disease clinical trials, and it avoids the limitations of timelines based on chronological age. FUNDING: National Institute on Aging and the National Institute for Child Health and Human Development.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Schworer EK, Zammit MD, Wang J, et al. Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study. Lancet Neurol. 2024. PMID: 39577922. doi:10.1016/S1474-4422(24)00426-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。